ES2184869T3 - Vacuna sub-unitaria contra la infeccion por flavivirus. - Google Patents
Vacuna sub-unitaria contra la infeccion por flavivirus.Info
- Publication number
- ES2184869T3 ES2184869T3 ES96917828T ES96917828T ES2184869T3 ES 2184869 T3 ES2184869 T3 ES 2184869T3 ES 96917828 T ES96917828 T ES 96917828T ES 96917828 T ES96917828 T ES 96917828T ES 2184869 T3 ES2184869 T3 ES 2184869T3
- Authority
- ES
- Spain
- Prior art keywords
- flavivirus
- sub
- vaccine against
- against infection
- unit vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 241000710831 Flavivirus Species 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title 1
- 229940031626 subunit vaccine Drugs 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 241000725619 Dengue virus Species 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 238000010188 recombinant method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
LA INVENCION PRESENTA VACUNAS CAPACES DE DESENCADENAR LA PRODUCCION DE ANTICUERPOS NEUTRALIZANTES CONTRA FLAVIVIRUS, QUE CONTIENEN, COMO PRINCIPIO ACTIVO, UNA PROTEINA DE LA CUBIERTA SEGREGADA PRODUCIDA POR TECNICAS RECOMBINANTES O UNA SUBUNIDAD. EN LAS REALIZACIONES QUE SE PRESENTAN, SE SEGREGAN EL DOMINIO B O EL 60-80 % DE LAS PORCIONES N - TERMINAL DE LA PROTEINA DE LA CUBIERTA (E) DEL VIRUS DEL DENGUE. EL PRODUCTO SEGREGADO PUEDE PURIFICARSE Y PREPARARSE FACILMENTE COMO VACUNA.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44873495A | 1995-05-24 | 1995-05-24 | |
US48880795A | 1995-06-07 | 1995-06-07 | |
US50046995A | 1995-07-10 | 1995-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2184869T3 true ES2184869T3 (es) | 2003-04-16 |
Family
ID=27412379
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES96917828T Expired - Lifetime ES2184869T3 (es) | 1995-05-24 | 1996-05-24 | Vacuna sub-unitaria contra la infeccion por flavivirus. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6165477A (es) |
EP (1) | EP0836482B1 (es) |
AT (1) | ATE227584T1 (es) |
AU (1) | AU716676B2 (es) |
CA (1) | CA2224724C (es) |
DE (1) | DE69624815T2 (es) |
DK (1) | DK0836482T3 (es) |
ES (1) | ES2184869T3 (es) |
PT (1) | PT836482E (es) |
WO (1) | WO1996037221A1 (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6074865A (en) * | 1995-07-20 | 2000-06-13 | The United States Of America As Represented By The Secretary Of The Army | Recombinant dengue virus DNA fragment |
CU22666A1 (es) * | 1996-11-25 | 2001-04-27 | Inst De Medicina Tropical Pedro Kouri | Procedimiento para la expresión de genes de los virus del dengue en la levadura pichia pastoris, adns recombinantes y microorganismos transformados |
AU2002300271B8 (en) * | 1997-07-31 | 2006-08-10 | Hawaii Biotech, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
EP1005363B1 (en) * | 1997-07-31 | 2006-03-29 | Hawaii Biotech, Inc. | Recombinant dimeric envelope vaccine against flaviviral infection |
FR2767324B1 (fr) * | 1997-08-14 | 2001-04-06 | Pasteur Institut | Utilisation de proteines d'enveloppe recombinantes pour le diagnostic du virus de la dengue |
US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
US7227011B2 (en) * | 1998-06-04 | 2007-06-05 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US7417136B1 (en) | 1998-06-04 | 2008-08-26 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention | Nucleic acid vaccines for prevention of flavivirus infection |
US6416763B1 (en) | 1998-08-28 | 2002-07-09 | Hawaii Biotechnology Group, Inc. | Recombinant nonstructural protein subunit vaccine against flaviviral infection |
US6432411B1 (en) | 1999-07-13 | 2002-08-13 | Hawaii Biotechnology Group | Recombinant envelope vaccine against flavivirus infection |
ES2374131T3 (es) | 2000-02-16 | 2012-02-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Flavivirus quiméricos avirulentos e inmunógenos. |
JP2003531128A (ja) * | 2000-04-14 | 2003-10-21 | インターツェル・アクチェンゲゼルシャフト | 修飾ペプチドを含む医薬調製物 |
US6682909B2 (en) * | 2000-09-13 | 2004-01-27 | Hawaii Biotech, Inc. | Immunogenic composition of hepatitis C and methods of use thereof |
WO2002072036A2 (en) * | 2001-03-12 | 2002-09-19 | Yale University | Compositions and methods comprising west nile virus polypeptides |
CU23245A1 (es) * | 2001-07-16 | 2007-10-17 | Inst De Medicina Tropical Pedr | CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS |
AU2003205169A1 (en) * | 2002-01-15 | 2003-07-30 | Acambis, Inc. | Viral vaccine production method |
US7476390B2 (en) | 2002-02-26 | 2009-01-13 | Maxygen, Inc. | Flavivirus antigens |
AU2003263853A1 (en) * | 2002-08-16 | 2004-03-03 | Board Of Regents The University Of Texas System | Compositions and methods related to flavivirus envelope protein domain iii antigens |
US7419789B2 (en) * | 2002-11-05 | 2008-09-02 | Institut Pasteur | Method of inhibiting binding of Dengue virus to a human cell with DC-SIGN blockers |
WO2004052293A2 (en) * | 2002-12-11 | 2004-06-24 | Hawaii Biotech, Inc. | Recombinant vaccine against flavivirus infection |
US20050287170A1 (en) * | 2002-12-11 | 2005-12-29 | Hawaii Biotech, Inc. | Subunit vaccine against West Nile viral infection |
PT1685251E (pt) * | 2003-10-10 | 2014-04-15 | Powderject Vaccines Inc | Construções de ácido nucleico |
US20070269461A1 (en) * | 2004-01-04 | 2007-11-22 | Sudhanshu Vrati | Recombinant Vaccine Against Japanese Encephalitis Virus (Jev) Infection and a Method Thereof |
US8900644B2 (en) * | 2004-12-22 | 2014-12-02 | Colgate-Palmolive Company | Oral care compositions containing compounds from magnolia and hops extracts |
CU23578A1 (es) | 2005-09-16 | 2010-09-30 | Ct Ingenieria Genetica Biotech | Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal |
CU23630A1 (es) | 2006-10-30 | 2011-02-24 | Ct Ingenieria Genetica Biotech | Moléculas peptídicas quiméricas con propiedades antivirales contra los virus de la familia flaviviridae |
EP2234624B1 (en) * | 2008-01-11 | 2018-06-20 | Inovio Pharmaceuticals, Inc. | Novel vaccines against multiple subtypes of dengue virus |
AU2010257162B2 (en) | 2009-05-31 | 2014-12-04 | Merck Sharp & Dohme Corp. | Recombinant subunit West Nile virus vaccine for protections of human subjects |
CA2770888C (en) | 2009-08-31 | 2020-04-14 | Gen-Probe Incorporated | Dengue virus assay |
WO2012027473A2 (en) * | 2010-08-24 | 2012-03-01 | The University Of North Carolina At Chapel Hill | Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens |
KR20130138789A (ko) * | 2010-10-29 | 2013-12-19 | 머크 샤프 앤드 돔 코포레이션 | 재조합 서브유닛 뎅기 바이러스 백신 |
CA3177572A1 (en) | 2013-03-15 | 2014-09-25 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
EP3490595A4 (en) * | 2016-07-27 | 2020-07-15 | Hawaii Biotech Inc. | OPTIMIZED ZIKAVIRUS ENVELOPES AND EXPRESSION THEREOF |
DK3620174T3 (da) | 2018-09-05 | 2022-03-14 | Takeda Vaccines Inc | Enhedsdosis af dengue-vaccine og indgivelse deraf |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0768267B2 (ja) * | 1986-06-05 | 1995-07-26 | 財団法人阪大微生物病研究会 | フラビウイルス抗原 |
US5013652A (en) * | 1986-10-14 | 1991-05-07 | Genex Corporation | Composite yeast vectors |
IL91304A0 (en) * | 1988-08-20 | 1990-03-19 | Us Health | Recombinant vaccinia virus for prevention of disease caused by flavivirus |
FR2665710A1 (fr) * | 1990-08-10 | 1992-02-14 | Pasteur Institut | Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques. |
US5514375A (en) * | 1990-08-15 | 1996-05-07 | Virogenetics Corporation | Flavivirus recombinant poxvirus vaccine |
MY109299A (en) * | 1990-08-15 | 1996-12-31 | Virogenetics Corp | Recombinant pox virus encoding flaviviral structural proteins |
US5494671A (en) * | 1990-08-27 | 1996-02-27 | The United States Of America As Represented By The Department Of Health And Human Services | C-terminally truncated dengue and Japanese encephalitis virus envelope proteins |
WO1992003161A1 (en) * | 1990-08-27 | 1992-03-05 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Flavivirus envelope proteins with increased immunogenicity for use in immunization against virus infection |
-
1996
- 1996-05-24 DK DK96917828T patent/DK0836482T3/da active
- 1996-05-24 WO PCT/US1996/007627 patent/WO1996037221A1/en active IP Right Grant
- 1996-05-24 EP EP96917828A patent/EP0836482B1/en not_active Expired - Lifetime
- 1996-05-24 CA CA 2224724 patent/CA2224724C/en not_active Expired - Lifetime
- 1996-05-24 AT AT96917828T patent/ATE227584T1/de active
- 1996-05-24 PT PT96917828T patent/PT836482E/pt unknown
- 1996-05-24 DE DE1996624815 patent/DE69624815T2/de not_active Expired - Lifetime
- 1996-05-24 ES ES96917828T patent/ES2184869T3/es not_active Expired - Lifetime
- 1996-05-24 AU AU60239/96A patent/AU716676B2/en not_active Expired
-
1997
- 1997-08-20 US US08/915,152 patent/US6165477A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ATE227584T1 (de) | 2002-11-15 |
AU716676B2 (en) | 2000-03-02 |
EP0836482A4 (en) | 1999-09-01 |
AU6023996A (en) | 1996-12-11 |
DE69624815T2 (de) | 2003-07-10 |
EP0836482B1 (en) | 2002-11-13 |
DK0836482T3 (da) | 2003-02-17 |
PT836482E (pt) | 2003-02-28 |
CA2224724A1 (en) | 1996-11-28 |
DE69624815D1 (de) | 2002-12-19 |
CA2224724C (en) | 2007-12-04 |
WO1996037221A1 (en) | 1996-11-28 |
EP0836482A1 (en) | 1998-04-22 |
US6165477A (en) | 2000-12-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2184869T3 (es) | Vacuna sub-unitaria contra la infeccion por flavivirus. | |
CY1105389T1 (el) | Hpv-e7 ως αγωγη εναντι του ιου θηλωματων ανθρωπου | |
EA200601575A1 (ru) | Казеиновые пептиды и их терапевтическое применение | |
ES2190799T3 (es) | Inmunogenos peptidicos para vacunacion y tratamiento de la alergia. | |
ES2156110T3 (es) | Analogos de sub-unidades de toxina del colera derivados de adn recombinante. | |
CY1107628T1 (el) | Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων | |
ES2187798T3 (es) | Procedimiento de conservacion de virus recombinantes infecciosos, suspension acuosa viral y su utilizacion como medicamento. | |
AR027391A1 (es) | Composiciones farmaceuticas de toxina botulinica | |
ATE350010T1 (de) | Zusammensetzung zur topischen anwendung | |
MXPA05009580A (es) | Vacuna contra el virus de la influenza. | |
ECSP105739A (es) | Anticuerpos de neutralización contra gdf-8 | |
BR0109346A (pt) | Combinações de substâncias ativas com propriedades inseticidas e acaricidas | |
ES2141065T1 (es) | Preparacion de vacunas subunitarias contra el virus sincitial respiratorio. | |
CY1105008T1 (el) | Αντιμικροβιακη ενεργοτητα του πρωτου κατιονικου συγκροτηματος της ανθρωπινης λακτοφερρινης | |
AR010583A1 (es) | CULTIVO DE CÉLULAS DE UNA CEPA DERIVADA DE UNA CEPA PROGENITORA DE UNA ESPECIE DE NEOSPORA, VACUNA QUE LAS CONTIENE, Y COMPOSICIoN. | |
DE60024100D1 (de) | Von dem syndrom der weissen flecken virus abgeleitete proteine und deren verwendungen | |
BR0316291A (pt) | Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv | |
ATE458496T1 (de) | Hiv-vakzine und anwendungsverfahren | |
CR7806A (es) | Inhibidores de la fusion de derivados peptidos de la infeccion vih | |
KR100725637B1 (en) | Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein | |
ES2078971T3 (es) | Produccion de virus y purificacion de proteinas con envoltura virica para uso en vacunas. | |
EA200100700A1 (ru) | Гены и белки и их применение | |
CY1107560T1 (el) | Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο | |
ES2180750T3 (es) | Conjugado de un principio activo, un polieter y, en caso dado, una proteina nativa no considerada como exogena. | |
BR9808226A (pt) | Coronavìrus respiratório bovino como uma vacina |